Sparfloxacin
Sparfloxacin Brand names, Sparfloxacin Analogs
Sparfloxacin Brand Names Mixture
- No information avaliable
Sparfloxacin Chemical_Formula
C19H22F2N4O3
Sparfloxacin RX_link
http://www.rxlist.com/cgi/generic2/sparfloxacin.htm
Sparfloxacin fda sheet
Sparfloxacin msds (material safety sheet)
Sparfloxacin Synthesis Reference
No information avaliable
Sparfloxacin Molecular Weight
392.4 g/mol
Sparfloxacin Melting Point
No information avaliable
Sparfloxacin H2O Solubility
Practically insoluble
Sparfloxacin State
Solid
Sparfloxacin LogP
1.695
Sparfloxacin Dosage Forms
Tablets (200-mg round, white, film-coated)
Sparfloxacin Indication
For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).
Sparfloxacin Pharmacology
Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.
Sparfloxacin Absorption
Well absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.
Sparfloxacin side effects and Toxicity
Single doses of sparfloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post-treatment observation period at the highest oral doses tested, up to 5000 mg/kg in either rodent species, or up to 600 mg/kg in the dog. Clinical signs observed included inactivity in mice and dogs, diarrhea in both rodent species, and vomiting, salivation, and tremors in dogs.
Sparfloxacin Patient Information
Sparfloxacin Organisms Affected
Enteric bacteria and other eubacteria
